Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC as Adjuvant to Opioid Treatment in Chronic Neuropathic Pain
NCT01840345Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acetylcysteine in neuropathic pain, sponsored by Virginia Commonwealth University. Primary endpoint: Opioid Use at 4 weeks. Started Jan 2014; status: completed.
02
Drugs
acetylcysteine
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT01840345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01840345.